Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis. PERSIAN trial: ...
The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...
Outcomes of initial vs delayed docetaxel therapy in veterans with metastatic hormone sensitive prostate cancer and high volume of disease. Evaluation of de novo oligometastatic, oligorecurrent, and ...
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination ...
High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...
The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk prostate cancer, according to findings presented in ASCO ...
A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...
For men with a localized recurrence following prostate cancer radiotherapy, salvage treatment with either focal therapy or surgery may offer comparable long-term cancer control, but focal therapy ...
For decades, testosterone therapy was largely considered dangerous for men with a history of prostate cancer. Now, ...
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results